Drug Shortage Active
MORPHINE SULFATE is currently in shortage. Reason: Unavailable. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
MORPHINE SULFATE (morphine sulfate) by Pfizer is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 2011.
Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
Morphine Sulfate is a full mu-opioid receptor agonist indicated for pain management via injection. It works by binding to opioid receptors in the CNS to produce analgesia without a ceiling effect, with dosing titrated to balance efficacy against adverse effects like respiratory depression.
Peak lifecycle stage suggests stable mature portfolio with established brand infrastructure and moderate commercial team investment.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Worked on MORPHINE SULFATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Morphine Sulfate offers stable career experience in a mature, essential pharmaceutical product with established markets and regulatory frameworks. Current supply shortage presents unique operational challenges in manufacturing, supply chain, and market access roles.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo